Estimated Time to Read: 8 minutes

Texas State Rep. James Frank (R-Wichita Falls), who now chairs the newly created House Select Committee on Health Care Affordability, has filed a class action lawsuit against Blue Cross Blue Shield of Texas (BCBSTX), alleging the insurer intentionally concealed prescription drug rebates in order to inflate insurance costs for Texas employers.

The lawsuit, filed in Dallas County District Court, claims BCBSTX knowingly reported inflated prescription drug costs to employer-sponsored health plans while failing to disclose substantial rebates it allegedly received through a pharmacy benefit manager (PBM) it partially owns. At the center of the lawsuit is an accusation that Blue Cross used gross prescription drug costs rather than net costs after rebates when calculating premiums, administrative fees, and stop-loss insurance charges for self-insured employers. According to the complaint, that practice allowed the insurer to pocket rebate revenue while Texas businesses paid artificially inflated costs for health coverage.

The lawsuit is notable not only because of the allegations themselves, but because it comes from a sitting state lawmaker who now oversees a legislative committee specifically tasked with studying health care affordability in Texas.

What the Blue Cross Blue Shield Lawsuit Alleges

The plaintiffs in the lawsuit are Sharp Iron Group LLC and Texas Transland LLC, both Wichita Falls-based companies led by Rep. Frank.

According to the filing, BCBSTX of Texas allegedly engaged in a multi-year scheme involving PBM rebates generated through Prime Therapeutics, a PBM partially owned by BCBS entities. The lawsuit claims BCBSTX would report prescription drug spending using gross prices before rebates, receive substantial manufacturer rebates through its affiliated PBM, conceal those rebates from employers sponsoring health plans, and use inflated cost figures to justify higher premiums and fees.

The complaint repeatedly argues that the “true” cost of prescription drugs should have reflected net costs after rebates rather than pre-rebate gross prices. According to the lawsuit, rebates on some prescription drugs allegedly amounted to 15% to 30% or more of gross drug spending. The filing further alleges that these inflated figures were then carried forward year after year in premium calculations and stop-loss pricing models, compounding financial harm to employers over time.

The plaintiffs accuse BCBSTX of fraud, fraudulent concealment, unjust enrichment, conversion, breach of fiduciary duty, and violations of the Texas Deceptive Trade Practices Act (DTPA).

The Lawsuit’s Focus on Pharmacy Benefit Managers

One of the biggest takeaways from the lawsuit is its focus on pharmacy benefit managers, commonly known as PBMs, which operate as middlemen between insurers, drug manufacturers, and pharmacies. They negotiate rebates with pharmaceutical companies, manage formularies, and process prescription drug claims.

Critics across the political spectrum have increasingly argued that PBMs contribute to rising health care costs through opaque pricing arrangements and rebate structures that are difficult for employers and consumers to evaluate.

The lawsuit directly attacks what it describes as a structural conflict of interest created by vertical integration between insurers and PBMs. Specifically, the complaint alleges Blue Cross profited twice from prescription drug transactions by charging employers based on gross drug costs while separately retaining rebates generated through its PBM ownership structure.

The lawsuit also claims the largest insurer-owned PBMs now process roughly 85% of prescriptions in Texas, giving them enormous leverage and visibility into drug pricing and rebate structures.

The Scope of the Proposed Class Action

The lawsuit seeks certification of a sweeping class action covering: “All employers in Texas that procured health insurance or plan administration services from BCBSTX from March 1, 2006, to the present.” If certified, the case could potentially involve thousands of Texas employers.

The complaint claims Blue Cross holds more than 37% of the Texas health insurance market and serves a massive number of employer-sponsored health plans across the state. The plaintiffs argue the alleged conduct affected employers in substantially similar ways because Blue Cross allegedly used the same pricing and reporting practices across its health plans.

The lawsuit seeks actual damages, disgorgement of retained PBM rebates, treble damages under the Texas DTPA, and exemplary damages. The filing even alleges that some of the conduct could constitute criminal violations under Texas law involving fiduciary misapplication and fraudulent securing of document execution.

Rep. Frank also publicly addressed questions about financial motives behind the lawsuit, stating on social media: “To be clear, any monetary recovery from this lawsuit will be used for the benefit of employees. I will receive nothing personally from any judgment or settlement.”

That statement is particularly notable given Frank’s dual role as both a plaintiff tied to the affected companies and the chairman of the House Select Committee on Health Care Affordability, which is expected to examine many of the same policy issues raised in the lawsuit as a part of its interim charges and jurisdiction.

PBM Reform Could Become Major Session Fight

The political implications of this lawsuit may prove just as significant as the legal claims themselves.

The Texas House recently created the Select Committee on Health Care Affordability to study rising health care costs and market distortions. State Rep. James Frank (R-Wichita Falls) chairs that committee.

That means the chairman overseeing the Legislature’s health care affordability discussions is simultaneously leading a major lawsuit against the state’s largest health insurer over alleged pricing practices. This dramatically increases the likelihood that PBM transparency, insurer disclosure requirements, prescription drug pricing practices, and rebate pass-through reforms will become central issues during the next legislative session.

That possibility becomes even more significant considering the broader leadership interest in pharmaceutical pricing issues inside the Texas Capitol.

Current Texas House Speaker Dustin Burrows (R-Lubbock) has previously filed legislation relating to pharmaceutical pricing transparency and international drug pricing disparities.

During the 84th Legislative Session (2015), Burrows filed legislation creating an interim committee to study international pharmaceutical price discrimination and examine the extent to which Americans subsidize international pharmaceutical markets and research costs. Though it was granted a hearing in the former House International Trade and Intergovernmental Affairs Committee, it was ultimately left pending.

Then, during the 85th Legislative Session (2017), Burrows filed legislation relating to importing FDA-approved pharmaceuticals from foreign countries. The proposal would have allowed Texans, pharmacists, and physicians to obtain FDA-approved drugs from foreign pharmacies or manufacturers and included liability protections for medical professionals acting in good faith. That legislation never received a hearing in the House Public Health Committee.

While those earlier efforts focused more directly on pharmaceutical manufacturers and international drug pricing, they nevertheless demonstrate that concerns surrounding pharmaceutical affordability and market distortions have already attracted attention from some of the most influential lawmakers in the Texas government.

Lawmakers in both parties have increasingly expressed frustration over opaque pricing systems within health care markets. PBMs in particular have become targets of bipartisan scrutiny nationwide.

This lawsuit could accelerate calls in Texas for legislation requiring greater rebate transparency, expanded audit rights for employers, mandatory pass-through pricing models, or restrictions on vertically integrated PBM arrangements. The lawsuit itself repeatedly argues that employers lacked visibility into rebate contracts, rebate payment records, and internal accounting systems.

That argument aligns closely with broader policy concerns that employers and consumers often have little insight into how prescription drug prices are actually determined.

Why This Lawsuit Matters for Texas Employers

For Texas employers, especially self-insured businesses, the case raises important questions about how health insurance costs are calculated and disclosed.

Many employers rely heavily on insurers and PBMs to administer increasingly complex prescription drug benefits. The lawsuit argues that employers often lack the contractual leverage or informational access necessary to independently verify the underlying economics of those arrangements.

If courts ultimately determine that rebate structures were improperly concealed or misrepresented, the ramifications could extend well beyond Blue Cross. Other insurers and PBMs operating in Texas could face increased legal scrutiny, legislative oversight, and demands for greater transparency.

At a minimum, the lawsuit appears poised to intensify public debate over the role of PBMs in rising health care costs and whether Texas lawmakers should pursue additional reforms targeting prescription drug pricing structures.

Conclusion

State Rep. James Frank’s lawsuit against Blue Cross Blue Shield of Texas is more than just a private legal dispute between an employer and an insurer. It is rapidly shaping into a broader political and policy battle over pharmacy benefit managers, health insurance transparency, and the true drivers of rising health care costs in Texas.

The lawsuit alleges Blue Cross systematically concealed PBM rebates while inflating the prescription drug cost figures used to calculate premiums and fees for Texas employers. Whether those allegations are ultimately proven in court remains uncertain.

But with the chairman of the Texas House Select Committee on Health Care Affordability now leading the charge, the case virtually guarantees that PBM reform, insurer transparency, and employer-sponsored health care costs will become major issues in the Texas Capitol going into the next legislative session.

---